Séverine Cunat1, Pascale Hoffmann, Pascal Pujol. 1. Laboratoire de Biologie Cellulaire, Centre Hospitalier Universitaire de Montpellier, Hôpital Arnaud de Villeneuve, Montpellier Cedex 5, France.
Abstract
OBJECTIVE: Molecular mechanisms involved in ovarian carcinogenesis are still unclear, but there is growing evidence that estrogens promote tumor progression in an epithelial ovarian cancer (EOC) subgroup. METHODS: We reviewed current knowledge on the effects of estrogens in ovarian carcinogenesis and new potential research focuses concerning hormonal therapy of EOC. RESULTS: Experimentally, estrogen stimulates the growth of ovarian tumor cell lines expressing estrogen receptors (ER). We and other authors have demonstrated differential expression of ERalpha or beta during ovarian carcinogenesis, with overexpression of ERalpha as compared to ERbeta in cancer. This differential expression in ER suggests that estrogen-induced proteins may act as ovarian tumor-promoting agents. Among these proteins, c-myc, fibulin-1, cathepsin-D, or several kallikreins may play a role, since high expression levels have been found in EOC. Consistently, recent prospective epidemiological studies have indicated that estrogen replacement therapy in postmenopausal women may increase ovarian cancer incidence and mortality. CONCLUSION: Questions on the estrogen-sensitivity and potential benefits of new hormone therapies in an EOC subgroup should be readdressed in the light of recent experimental and clinical data.
OBJECTIVE: Molecular mechanisms involved in ovarian carcinogenesis are still unclear, but there is growing evidence that estrogens promote tumor progression in an epithelial ovarian cancer (EOC) subgroup. METHODS: We reviewed current knowledge on the effects of estrogens in ovarian carcinogenesis and new potential research focuses concerning hormonal therapy of EOC. RESULTS: Experimentally, estrogen stimulates the growth of ovarian tumor cell lines expressing estrogen receptors (ER). We and other authors have demonstrated differential expression of ERalpha or beta during ovarian carcinogenesis, with overexpression of ERalpha as compared to ERbeta in cancer. This differential expression in ER suggests that estrogen-induced proteins may act as ovarian tumor-promoting agents. Among these proteins, c-myc, fibulin-1, cathepsin-D, or several kallikreins may play a role, since high expression levels have been found in EOC. Consistently, recent prospective epidemiological studies have indicated that estrogen replacement therapy in postmenopausal women may increase ovarian cancer incidence and mortality. CONCLUSION: Questions on the estrogen-sensitivity and potential benefits of new hormone therapies in an EOC subgroup should be readdressed in the light of recent experimental and clinical data.
Authors: Ken Yamaguchi; Zhiqing Huang; Noriomi Matsumura; Masaki Mandai; Takako Okamoto; Tsukasa Baba; Ikuo Konishi; Andrew Berchuck; Susan K Murphy Journal: Int J Cancer Date: 2014-01-14 Impact factor: 7.396
Authors: Sakthivel Muniyan; Yu-Wei Chou; Te-Jung Tsai; Paul Thomes; Suresh Veeramani; Benedict B Benigno; L DeEtte Walker; John F McDonald; Shafiq A Khan; Fen-Fen Lin; Subodh M Lele; Ming-Fong Lin Journal: Mol Carcinog Date: 2014-01-07 Impact factor: 4.784
Authors: Ellen T Chang; Valerie S Lee; Alison J Canchola; Christina A Clarke; David M Purdie; Peggy Reynolds; Hoda Anton-Culver; Leslie Bernstein; Dennis Deapen; David Peel; Rich Pinder; Ronald K Ross; Daniel O Stram; Dee W West; William Wright; Argyrios Ziogas; Pamela L Horn-Ross Journal: Am J Epidemiol Date: 2007-01-08 Impact factor: 4.897
Authors: Allison C Sharrow; Brigitte M Ronnett; Christopher J Thoburn; James P Barber; Robert L Giuntoli; Deborah K Armstrong; Richard J Jones; Allan D Hess Journal: J Ovarian Res Date: 2010-03-31 Impact factor: 4.234
Authors: Jonathan L Hecht; Joanne Kotsopoulos; Susan E Hankinson; Shelley S Tworoger Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-04-21 Impact factor: 4.254